Novartis distances itself from Pixuvri
This article was originally published in Scrip
Novartis will not be exercising its option for Cell Therapeutics' non-Hodgkin's lymphoma drug Pixuvri (pixantrone), which it has held since 2006, despite the product finally winning round Europe's reimbursement authorities. It is also returning rights to Opaxio (paclitaxel poliglumex), which it acquired under the same agreement (scripintelligence.com, 22 September 2006). Novartis has failed to show any real interest in either drug since signing the deal.
You may also be interested in...
Brands unfairly maligned by powerful influencers, strictly on behalf of paying competitors, could have occasion to broach the subject with the US Federal Trade Commission, which seeks comment on its “Endorsement Guides” in an increasingly complex and competitive, digitized advertising environment.
At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages under FTC Act provisions.
The US agency has suspended all routine surveillance inspections in China through the end of March because of coronavirus fears, commissioner Stephen Hahn announced late on 14 February. Despite expecting medical product shortages, Hahn said the agency is being proactive: “We are not waiting for drug and device manufacturers to report shortages to us” before acting. The timing of Hahn’s statement – at 6 p.m. EST on a Friday, at the beginning of a three-day US holiday weekend – suggests he isn’t particularly excited to share the information.